<DOC>
	<DOCNO>NCT02249442</DOCNO>
	<brief_summary>To determine pharmacokinetics single-dose steady-state Tipranavir/Ritonavir ( TPV/r ) 500/200 mg subject mild moderate hepatic insufficiency</brief_summary>
	<brief_title>Study Determine Pharmacokinetics TPV/r Subjects With Mild Moderate Hepatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation . 2 . Male female subject : Diagnostically establish hepatic disease mild hepatic insufficiency ( define maximum ever ChildPugh score ≤6 ) Diagnostically establish hepatic disease moderate hepatic insufficiency ( define maximum ever ChildPugh score ≤9 ) less 5 year . Current ChildPugh score must less 9 Subjects match gender , race , age ( ±3 year ) , weight ( ±3 kg ) cigarette smoking ( match possible +/ .25 pack year ) subject mild moderate hepatic impairment already enrol study . 3 . Body Mass Index ( BMI ) 18 29 kg/m2 4 . Subjects ≥18 ≤75 year old . 5 . Ability swallow multiple large capsule without difficulty . 6 . Laboratory value indicate adequate baseline organ function require time screen . All subject ( include healthy control ) laboratory value less equal Grade 1 , base AIDS Clinical Trial Group ( ACTG ) Grading Scale.The follow exception make subject mild moderate hepatic insufficiency : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal ( ULN ) ( ≤ Grade 2 ) Alkaline Phosphatase &lt; 2 x ULN Hemoglobin &gt; 10.0 g / dL Platelets &gt; 75,000 / μl 7 . Willingness abstain alcohol start 2 day prior administration study drug end study . 8 . Willingness abstain follow 72 hour prior pharmacokinetic ( PK ) sampling : Garlic supplement , methylxanthine contain drink ( coffee , tea , cola , energy drink , chocolate , etc. ) . 9 . Willingness abstain counter herbal medication duration study . 10 . Acceptable medical history , physical examination chest Xray ( investigator 's discretion ) require prior enter treatment phase study . 11 . Willingness abstain follow start 14 day prior administration study drug end study : Grapefruit grapefruit juice ; Red wine ; Seville orange ( marmalade ) ; St. John 's Wort Milk Thistle . 12 . Willingness abstain vigorous physical exercise intense PK study day ( Days 1 7 ) . 13 . Reasonable probability completion study , include dosing requirement TPV/r risk hepatic decompensation among subject mild moderate hepatic insufficiency . 1 . Female subject reproductive potential : Have positive serum βhCG ( Human chorionic gonadotropin test pregnancy ) Visit 1 Day 0 . Have use barrier contraceptive method least 3 month prior Day 0 ( Visit 2 ) . Are willing use reliable method least barrier contraception , trial 60 day completion/termination . Are breastfeed . 2 . Participation another trial investigational medicine within 60 day prior Day 0 ( Visit 2 ) . 3 . Use medication list protocol within 30 day prior Day 0 ( Visit 2 ) . 4 . Use pharmacological contraceptive ( include oral patch ) one month prior study initiation duration study . Use implantable injectable contraceptive agent exclude least six month prior study start . 5 . Use hormone replacement therapy estrogenbased preparation least 1 month prior study initiation duration study . 6 . Administration antimicrobial agent within 10 day prior Day 0 ( Visit 2 ) trial . 7 . Subjects history spontaneous bacterial peritonitis , advance hepatic cirrhosis ( include Child'sPugh score &gt; 8 ) , active esophageal variceal disease , asterixis . 8 . Subjects active untreated hepatocellular carcinoma test positive serum alpha fetoprotein ( &gt; 10mg/dL ) . 9 . Subjects active coagulopathy . 10 . Have serological evidence exposure , infection , HIV . 11 . Recent history alcohol substance abuse ( within 6 month study period ) . 12 . Blood plasma donation within 30 day prior Day 0 ( Visit 2 ) . 13 . Subjects seat systolic blood pressure either &lt; 100 mm Hg &gt; 150 mm Hg ; rest heart rate either &lt; 50 beats/min &gt; 90 beats/min . For subject rest heart rate 50 , 90 , investigator could discuss exclusion medical monitor casebycase basis . 14 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer TPV ritonavir ( RTV ) . 15 . Subjects acute illness within 2 week prior Day 0 ( Visit 2 ) . 16 . Current use medication control symptoms hepatic disease within 30 day prior Day 0 , ( Visit 2 ) duration trial . 17 . Known hypersensitivity TPV , Ritonavir sulphonamide class drug . 18 . Inability adhere requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>